Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.
Laurence Albigès, MD, PhD
Advertisement
Laurence Albigès, MD, PhD, is a medical oncologist and head of the Department of Oncology at Institut Gustave Roussy in Paris, France.
Articles by Laurence Albigès, MD, PhD
Laurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.
Laurence Albigès, MD, PhD discusses a biomarker analysis which evaluated the presence of circulating KIM-1 in patients with renal cell carcinoma.
Laurence Albigès, MD, PhD, discusses on the safety and efficacy of cabozantinib in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component.
Advertisement
Latest Updated Articles
Dr Albigès on Survival Outcomes With Cabozantinib Plus Nivolumab and Ipilimumab in RCCPublished: February 14th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5